comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 19:29:07 - browse：31

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Colorectal cancer study finds potential in overlooked immune cell

hotspot

WSS

Chemotherapy drug shortage eases slightly but still widespread

3 questions for the future of Biden's cancer moonshot

Was Amgen transparent enough on FDA's concern on cancer drug?

Why the quest to eradicate polio has stumbled

What to expect at HLTH 2023, the health care industry conference

Liquid biopsy for lung cancer is launched by Delfi

leisure time

comprehensive

explore

Walensky prepares to leave CDC — and Congress — behind

Physician executives need more than on

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Was Amgen transparent enough on FDA's concern on cancer drug?

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA panel signals lack of confidence in Amgen cancer drug data

Walensky prepares to leave CDC — and Congress — behind

How the messy conversation about Dolly changed bioethics

At least 13 dead in Texas as scorching temps continue

AI can decode, harness the power of the humane immune system

hotspot

Assistant physicians can help address the primary care shortage

3 questions for the future of Biden's cancer moonshot

Neurocrine congenital adrenal hyperplasia trial succeeds

Bristol 'take

Senate panel eyes new effort on drug shortages

Physician executives need more than on

hotspot

hotspot

focus

leisure time